Kornimate/medical-research-clean huggingface dataset:
virtual reality cognitive training for mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this study aims to assess the feasibility and efficacy of a 10-weekly multi-domain vrct program on the cognitive function (i.e. attention, memory, and executive functioning) of older adults with mci.

this study employed a pilot feasibility parallel design approach. participants were randomly assigned to either the vrct intervention group or the active control group. the outcome assessor was blinded. participants were recruited from outpatient clinics in changi general hospital, singapore. they were referred by treating geriatricians and psycho-geriatricians.

Eligibility criteria:
inclusion criteria: * aged 65-85 * diagnosis of mci by a clinician in accordance to petersen's criteria * mmse ≥ 23 * ability to see and hear * ability to read and write in either english or mandarin exclusion criteria: * diagnosed with a primary other neurocognitive disorder * diagnosed with major psychiatric illness such as major depressive disorder or anxiety disorder, severe visual or auditory impairment * diagnosed with serious medical illnesses including acute or severe asthma, severe or unstable cardiovascular disease, active gastric ulcer, severe liver disease or severe renal disease.
bax 826 dose-escalation safety study

Conditions: Hemophilia A

Summary: 1. to assess tolerability and safety of bax 826 after a single infusion in previously treated patients (ptps) with severe hemophilia a 2. to determine the pharmacokinetic (pk) parameters of bax 826 compared to advate 3. to evaluate immunogenicity of polysialic acid linked to factor viii (fviii)


Eligibility criteria:
inclusion criteria: 1. previously treated male participants aged 18 to 65 years (inclusive) at the time of screening 2. diagnosis of severe hemophilia a (factor viii level \<1%) 3. previously treated with fviii concentrates for ≥150 documented exposure days (eds) 4. karnofsky performance score of ≥60 5. human immunodeficiency virus negative (hiv-); or hiv+ with stable disease 6. hepatitis c virus negative (hcv-); or hcv+ with chronic stable hepatitis as assessed by the investigator 7. able to understand and have provided written informed consent including signature on an informed consent form (icf) approved by an ethics committee (ec) 8. have provided written authorization for use and disclosure of protected health information 9. agree to abide by the study schedule and to return for the required assessments 10. willing and able to comply with the requirements of the protocol exclusion criteria: 1. detectable fviii inhibitor at screening, with a titer ≥0.6 bethesda unit (bu) 2. documented history of fviii inhibitors with a titer ≥0.4 bu at any time prior to screening 3. known clinical hypersensitivity towards mouse or hamster proteins or to polysialic acid (psa) 4. scheduled elective surgery during study participation 5. severe chronic hepatic dysfunction 6. severe renal impairment 7. currently receiving, or has recently received (less than 3 months prior to study participation), or is scheduled to receive during the course of the study, other psa-ylated drugs 8. have received another investigational drug within 30 days prior to study entry and/or is scheduled to receive additional investigational drug during the course of the study in the context of another investigational drug study 9. diagnosis of an inherited or acquired hemostatic defect other than hemophilia a 10. currently receiving, or scheduled to receive during the course of the study, an immune-modulating drug other than antiretroviral chemotherapy 11. has a clinically significant medical, psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, would affect the safety or compliance of the participant during the study 12. is a family member or employee of the investigator
investigating healthcare disparities in vitiligo

Conditions: Vitiligo

Summary: vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.there are however, limited population-based studies on the burden of vitiligo and disparities across people of different ethnicities and deprivation. the overall purpose of this study is to provide an estimate of the lifetime risk of vitiligo in the population overall and by sociodemographic subgroups. moreover, to do a subgroup analysis in the vitiligo population to identify health-related disparities across people in different sex, age, deprivation and ethnicity. a detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.

this study will provide estimate of the cumulative lifetime risk of vitiligo in the population overall, and by important sociodemographic groups, including age, sex, ethnicity and deprivation, which will prevalent key data to show the relative burden of vitiligo across the aforementioned groups. these approaches allow creation of cumulative lifetime risk plots which provide an excellent and accessible way to display the relative disease burden across groups. the cumulative lifetime risk of vitiligo will be estimated at age 80 years (approximate lifetime expectancy in the uk) using survival models, with age as the timescale and accounting for competing risk of death. this study will also perform a subgroup analysis in the vitiligo population to identify health-related disparities across people in different deprivation, sex and ethnic groups. the disparities that will be considered are: mental health conditions; healthcare utilisation; and work impact (time off work and unemployment), the assessment of any associations with baseline characteristics and the outcome of interest will be used using cox proportional hazards models (time to event outcomes) and generalised linear models.

Eligibility criteria:
inclusion criteria: * the cohort for the endpoint analysis will consist of all adults and adolescents (aged 13+) contributing to opcrd during the study period (2004-2020). * the cohort for the lifetime risk analysis will consist of all people contributing to opcrd during the study period. * the vitiligo cohort consists of people newly diagnosed with vitiligo at any point during the study period. exclusion criteria: * people with the alternative non-vitiligo diagnoses (other hypopigmenting conditions). * people with vitiligo diagnosis within 6 months of practice registration. * people without vitiligo with less than 1 year of follow up within the dataset. * people over the age of 95 (for those reaching age 95 during the follow up period follow up was censored at age 95). * people who have opted out of record sharing.
a phase iii randomized, blind, double dummy, multicenter study assessing the efficacy and safety of iv thrombolysis (alteplase) in patients with acute central retinal artery occlusion

Conditions: Central Retinal Artery Occlusion

Summary: the aim of the theia study is to determine if alteplase administrated within 4.5 hours improve visual deficit due to acute crao with a good safety profile.


Eligibility criteria:
inclusion criteria: * patients aged up to 18 years * crao diagnosis by fundoscopic examination or non-mydriatic retinophotography (nmr) performed by an ophthalmologist. * blindness defined according to who classification as visual acuity \<1/20 (20/400). * treatment intervention should be initiated by a stroke team as quickly as possible and within 4.5 hours from symptom onset. * no clinical (e.g headache with jaw claudication or scalp tenderness, no temporal pulse) or laboratory evidence (elevated crp) of giant cell arteritis * no clinical or radiological evidence of stroke within the last 3 months. * patients covered by health care insurance (social security) * written informed consent obtained. exclusion criteria: * symptoms onset more than 4.5 h prior to infusion start or undetermined time of symptom onset. * minor va deficit or va rapidly improving before start of infusion. * crao without foveal ischemia. * other retinal vascular disease: occlusion of branch of the cra without significant va loss, occlusion of the retinal vein, proliferative diabetic retinopathy or any other severe retinopathy. * clinical or laboratory evidence of temporal arteritis. * evidence of ich or ischemic stroke on the pre-administration ct scan or mri. * pregnant or lactating women * minors * adults under guardianship or trusteeship * any contraindication to alteplase * any contraindication to aspirin

Keywords: central retinal artery occlusion visual acuity visual field mrs nei-vfq-25
the effect of refractive errors on central corneal thickness by using pentacam and iol master

Conditions: Central Corneal Thickness

Summary: to evaluate the impact of refractive errors on the central corneal thickness obtained by pentacam and intraocular lenses (iol) master in eyes with different refractive errors.

central corneal thickness (cct) is a key indicator of corneal health status and helps to assess corneal diseases. the normal corneal thickness is about 540 μm and mainly consists of the stroma, which is estimated at 450 μm in the center. the stroma provides vital structural integrity and plays a key role in helping maintain transparency. it has been reported, however, that cct follows a diurnal pattern being 10 μm thicker in the morning due to reduced evaporation of water from underneath the closed eyelids

Eligibility criteria:
inclusion criteria: * subjects included in this study aged between20 and 41 years, asked for refractive surgery exclusion criteria: * patients with corneal scarrig or opacification. * patients with corneal dystrophies. * patients with keratoconus. * previous ocular or refractive surgery. * ocular trauma. * uveitis patients. * patients with history of recent contact lens wear.
study of the role of interferon αon the endothelial dysfunction during septic shock

Conditions: Septic Shock

Summary: septic shock is the most severe form of a bacterial infection, affecting 24 million patients per year worldwide, with a high mortality (\> 30%). septic shock is defined by an acute circulatory failure, with low blood pressure and insufficient oxygen supply to organs. this circulatory failure is related to vascular damages, in which the endothelial vascular tissue is impaired by inflammatory mechanisms, with release of circulating endothelial cells in the blood. therefore, modulating inflammation on the vascular endothelial tissue could be a therapeutic strategy, and the investigators focus on the role of the type i interferons on the endothelial tissue because of the demonstrated role of type i interferons during septic shock. thus the investigators proceed to an observational study, in which the primary purpose will be to show a higher expression of type i interferon receptors on circulating endothelial cells in patients with septic shock compared to control subjects. concerning secondary purposes, the investigators will record mortality at d3, d7 and d28, perform assays about types i, ii and iii interferons in plasma, and test anti-interferon on endothelial cells ex vivo


Eligibility criteria:
* for all subjects * age \> 18 years old * for females: negative pregnancy test * subject covered by health insurance * written consent * patients with septic shock * patients must be in icu * septic shock defined by the sepsis-3 criteria \[1\] * inclusion within the 12 hours following the onset of norepinephrin * controls : * blood donors exclusion criteria: * moribund * age \< 18 years old * absence of written consent
outcome of surgery for idiopathic macular holes

Conditions: Idiopathic Macular Hole

Summary: retrospective medical chart review of patients undergoing surgical repair of idiopathic macular hole


Eligibility criteria:
inclusion criteria: * patient suffering from primary idiopathic macular hole and treated by retinal repair surgery exclusion criteria: * presence of other retinal disease
clearing the fog: is hydroxychloroquine effective in reducing covid-19 progression

Conditions: Covid19; Progression

Summary: brief summary: purpose of this study is to evaluate efficacy of hydroxychloroquine (hcq) in reducing progression of corona virus disease 2019 (covid - 19) and achieving viral clearance. condition or disease :i covid-19 ntervention/treatment :drug: hydroxychloroquine sulfate phase: phase iii

this study explores efficacy of hcq (400mg bd on d0 and 200mg bd d1-d5) in reducing progression of mild covid-19 patients and decreasing viral load. participants of study will be randomized 2:1 to receive either active drug or standard of care (soc) treatment respectively. we aim to demonstrate reduced covid-19 progression and early viral clearance in individuals on hcq therapy.

Eligibility criteria:
inclusion criteria: * mild corona virus disease (covid-19) * pcr confirmed infection * hospital admitted patients exclusion criteria: * moderate, severe and critical covid-19 * day 0 crp greater than 6mg/dl, alc \< 1000 or evidence of infiltrates on x-ray chest * comorbidity with life expectancy less than 6 months * contraindications to hcq therapy

Keywords: covid-19 viral clearance , mild infection disease progression trial hcq
comparing treatment of dry eye with intracanalicular dexamethasone, restasis, and/or lotemax

Conditions: Dry Eye

Summary: this 6 month study seeks to compare the use of intracanalicular dexamethasone in conjunction with restasis (cyclosporine ophthalmic emulsion) for the treatment of signs and symptoms of dry eye disease as compared to restasis with lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and restasis monotherapy.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * signs and symptoms of dry eye disease * consent to treat with topical immunomodulator * willing and able to comply with clinic visits and study related procedures * willing and able to sign the informed consent form exclusion criteria: * patients under the age of 18. * pregnancy (must be ruled out in women of child-bearing age with pregnancy test) * active infectious systemic disease * active infectious ocular or extraocular disease * altered nasolacrimal flow of either acquired, induced, or congenital origin * hypersensitivity to dexamethasone * patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit * patient being treated with either topical, oral, or intravenous immunosuppressive agents, immunomodulating agents, or steroid (including nsaids) * patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
study of the geometry of the immature human femur before the age of 3 years from data measured on ct scan

Conditions: Femur Fracture, Childhood

Summary: childhood fractures are the second most common presentation of abuse. the target population for screening for these injuries is children under the age of three who are unable to express themselves about the circumstances of the trauma, hence the need to develop a validated model to predict the outcome of trauma as well as the origin of a fracture. few morphological data are available in the literature for the femur concerning the period of rapid growth between 0 and 3 years of age.


Eligibility criteria:
inclusion criteria: * minor patient who died before the age of 3 years * whole body ct imaging performed post mortem on judicial requisition in the framework of a forensic procedure * absence of refusal in the medical file by the holders of parental authority concerning the re-use of their child's data for the purposes of this research exclusion criteria: * refusal manifested in the medical record by parental authority holders regarding the reuse of their child's data for the purpose of this research, * femur not fully assessable on imaging acquisition

Keywords: femur fracture, childhood
shared decision making in graves disease - graves disease (gd) choice

Conditions: Graves' Disease; Thyroid Disease; Hyperthyroidism

Summary: the investigators' decision aid for patients with gd, gd choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry experience, ii) input and involvement of patients, clinicians and other stakeholders, iii) direct observation of encounters and iv) extensive field-testing. the goal is to create a decision aid that will be rigorously evidence-based, clear and complete, able to be used by clinicians with minimal training time, while satisfying extant standards for rigorous high-quality shared decision making tools.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years * diagnosis of graves disease * appointment with endocrinologist to discuss treatment options for graves disease exclusion criteria: * major barriers to participate in shared decision making or to providing informed consent (i.e. dementia, severe hearing or visual impairment)

Keywords: grave's disease thyroid hyperthyroidism thyroidectomy radioactive iodine antithyroid shared decision making aid evidence based endocrinology mayo clinic
a study to examine safety, tolerability, pharmacokinetics and pharmacodynamics of exenatide once weekly in japanese patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: exenatide twice daily has been studied in japanese type 2 diabetes patients. a once-weekly version of exenatide is currently being evaluated. study gwbw is the first study of exenatide once weekly in japanese patients. this study is designed to evaluate safety and tolerability of exenatide once weekly in japanese patients and determine whether the dose selected for us and european development is appropriate for japanese patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * body weight ≥50 kg. * have suboptimal glycemic control as evidenced by an hba1c defined by the following criteria: \*6.5% to 10.0%, inclusive, at study start for patients managed with diet modification and exercise or treated with oral antidiabetics drug but not alpha glucosidase inhibitor or meglitinide derivatives; \*6.5% to 9.5%, inclusive, at study start for patients treated with oral antidiabetics including alpha glucosidase inhibitor or meglitinide derivatives. * have been treated with diet modification and exercise alone or in combination with a stable regimen of oral antidiabetic drugs (sulfonylurea, metformin and thiazolidinedione) for at least 2 months prior to study start. in the case of patients with concomitant use of sulfonylurea, the dose of sulfonylurea must not be more than maximum recommended dose. the patients with concomitant use of alpha glucosidase inhibitors (glucobay® \[acarbose\], basen® \[voglibose\], or seibule® \[miglitol\]) or meglitinide derivatives (glufast® \[mitiglinide\] or fastic®/starsis® \[nateglinide\]) can be included in this study, but these drugs must be discontinued after confirmation of eligibility at study start. exclusion criteria: * subjects who have donated more than 200 ml of blood and component blood donation within one month of study start, or those who have donated more than 400 ml of blood within three months of study start. * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * have participated and received at least one dose of exenatide or other glp-1 analogs in this study previously, or any other study using exenatide or other glp-1 analogs. * are treated with any exogenous insulin within 3 months of screening. * are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): \*drugs that directly affect gastrointestinal motility, including nauzelin® (domperidone), primperan®/terperan® (metoclopramide), ganaton® (itopride), acenalin® (cisapride), gasmotin® (mosapride), or cerekinon® (trimebutine). * females who are breastfeeding.

Keywords: exenatide byetta diabetes amylin lilly
wearable vibration effect on biomechanics and biomarkers after acl reconstruction

Conditions: Anterior Cruciate Ligament Injuries

Summary: anterior cruciate ligament (acl) injuries account for up to 25% of knee injuries, it is estimated that 32,000-400,000 new cases of acl tears occur in the usa every year. the standard care is twofold; a) acl reconstruction surgery and b) prolonged rehabilitation period (usually no less than 9 months). however, a large amount of patients do not return to their pre-injury activity level, and up to 30% reinjure their acl in the following two years. the wearable system consists of two non-invasive bands, above and below the knee that vibrate during the weight bearing phase while walking.

the objective of this study is to investigate the effect of treatment for acl reconstruction, including vibrational stimulation and pressure, on locomotion tasks (i.e. walking, stair ascending and descending), muscle function, and pain/function.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * males and females * aged 18-50 * scheduled for an acl reconstruction in rambam hospital. * hebrew language at mother tongue level exclusion criteria: * inability to understand the study protocol. * known neuropathies, active cancer, previous fractures in the lower limbs, inflammatory arthritis, implanted electronic devices of any kind. * allergies to silver or adhesives.

Keywords: knee pathology